JP2006508081A - ホスフィチル化方法 - Google Patents
ホスフィチル化方法 Download PDFInfo
- Publication number
- JP2006508081A JP2006508081A JP2004544427A JP2004544427A JP2006508081A JP 2006508081 A JP2006508081 A JP 2006508081A JP 2004544427 A JP2004544427 A JP 2004544427A JP 2004544427 A JP2004544427 A JP 2004544427A JP 2006508081 A JP2006508081 A JP 2006508081A
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- formula
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000005731 phosphitylation reaction Methods 0.000 title claims description 8
- 150000007530 organic bases Chemical class 0.000 claims abstract description 23
- 239000002777 nucleoside Substances 0.000 claims abstract description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 7
- 150000001298 alcohols Chemical class 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000001931 aliphatic group Chemical group 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 9
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 125000006242 amine protecting group Chemical group 0.000 claims description 5
- ZLRAAUUPULJGTL-UHFFFAOYSA-N diaminophosphinous acid Chemical compound NP(N)O ZLRAAUUPULJGTL-UHFFFAOYSA-N 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000006241 alcohol protecting group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 3
- YKLJUGWFWPZZFA-UHFFFAOYSA-N amino-(morpholin-4-ylamino)phosphinous acid Chemical compound NP(O)NN1CCOCC1 YKLJUGWFWPZZFA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- WDXCXSLEXBYOAV-UHFFFAOYSA-N n-[1-bis[di(propan-2-yl)amino]phosphanyloxypropan-2-yl]-2,2,2-trifluoroacetamide Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCC(C)NC(=O)C(F)(F)F WDXCXSLEXBYOAV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- ATPPRCQGQLBLHD-UHFFFAOYSA-N C1(=CC=CC=C1)C(C1=CC=CC=C1)[SiH2]CCOP Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)[SiH2]CCOP ATPPRCQGQLBLHD-UHFFFAOYSA-N 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 239000012190 activator Substances 0.000 abstract description 17
- 150000003573 thiols Chemical class 0.000 abstract description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 9
- 150000008300 phosphoramidites Chemical class 0.000 abstract description 6
- 125000003835 nucleoside group Chemical group 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- -1 nucleoside phosphoramidites Chemical class 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- 125000000217 alkyl group Chemical group 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 150000003512 tertiary amines Chemical class 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 229940081974 saccharin Drugs 0.000 description 5
- 235000019204 saccharin Nutrition 0.000 description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003216 pyrazines Chemical class 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 150000003557 thiazoles Chemical class 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical class C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- MNEIJGDSFRHGMS-UHFFFAOYSA-N 1-(phenylmethyl)benzimidazole Chemical class C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 MNEIJGDSFRHGMS-UHFFFAOYSA-N 0.000 description 1
- 125000004961 1-arylpyrazolyl group Chemical group 0.000 description 1
- NJZQOCCEDXRQJM-UHFFFAOYSA-N 1-benzylindole Chemical class C1=CC2=CC=CC=C2N1CC1=CC=CC=C1 NJZQOCCEDXRQJM-UHFFFAOYSA-N 0.000 description 1
- LQTMKPZRKXYOLG-UHFFFAOYSA-N 1-benzylpurine Chemical class C1=NC2=NC=NC2=CN1CC1=CC=CC=C1 LQTMKPZRKXYOLG-UHFFFAOYSA-N 0.000 description 1
- AKQAJYLKBCWJBV-UHFFFAOYSA-N 1-benzylpyrazole Chemical class C1=CC=NN1CC1=CC=CC=C1 AKQAJYLKBCWJBV-UHFFFAOYSA-N 0.000 description 1
- FNEQHKCQXDKYEO-UHFFFAOYSA-N 1-benzylpyrrole Chemical class C1=CC=CN1CC1=CC=CC=C1 FNEQHKCQXDKYEO-UHFFFAOYSA-N 0.000 description 1
- DBMKVSWIHRGBBC-UHFFFAOYSA-N 1-benzylpyrrolo[2,3-b]pyridine Chemical class C1=CC2=CC=CN=C2N1CC1=CC=CC=C1 DBMKVSWIHRGBBC-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical class C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- UAQOYBJXXMLVQI-UHFFFAOYSA-N 5-methyl-1h-pyrimidin-2-one Chemical compound CC1=CN=C(O)N=C1 UAQOYBJXXMLVQI-UHFFFAOYSA-N 0.000 description 1
- SHLJOANTPJWIHS-UHFFFAOYSA-N 5-methyl-1h-pyrimidin-6-one Chemical compound CC1=CN=CNC1=O SHLJOANTPJWIHS-UHFFFAOYSA-N 0.000 description 1
- SDIZCZTVHWHHHX-UHFFFAOYSA-N 5-methyl-2-(sulfanylidenemethylidene)-1h-pyrimidin-4-one Chemical compound CC1=CNC(=C=S)NC1=O SDIZCZTVHWHHHX-UHFFFAOYSA-N 0.000 description 1
- OWKFQGDPRUUKOJ-UHFFFAOYSA-N 5-methyl-6-methylsulfanyl-1h-pyrimidin-2-one Chemical compound CSC=1NC(=O)N=CC=1C OWKFQGDPRUUKOJ-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- IKZRFGGARFKJOA-UHFFFAOYSA-N 7h-purin-8-amine Chemical compound C1=NC=C2NC(N)=NC2=N1 IKZRFGGARFKJOA-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 0 BC(C1*)OC(CO*)C1OP(*)NCC Chemical compound BC(C1*)OC(CO*)C1OP(*)NCC 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 239000003341 Bronsted base Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- RFJDCAMETMDBBK-UHFFFAOYSA-N N-[2-benzhydrylsilylethoxy-[di(propan-2-yl)amino]phosphanyl]-N-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1C([SiH2]CCOP(N(C(C)C)C(C)C)N(C(C)C)C(C)C)C1=CC=CC=C1 RFJDCAMETMDBBK-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 150000003854 isothiazoles Chemical class 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical group ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【化1】
Description
多くの態様において、アルコールまたはチオールは、フリーのヒドロキシ基またはチオール基を含むヌクレオシドまたはオリゴヌクレオチドであり、それには、ヘキソースのような、天然のヌクレオシドペントース類および非天然のヌクレオシド糖類を含むヌクレオシドおよびオリゴヌクレオチドが含まれる。アルコールまたはチオールが、ヌクレオシドまたはオリゴヌクレオチドである場合、それは、しばしば、保護されたデオキシリボヌクレオシド、保護されたリボヌクレオシド、保護されたオリゴデオキシリボヌクレオチド、保護されたオリゴリボヌクレオチド、または、デオキシリボヌクレオチド部分とリボヌクレオチド部分の混合体を有する保護されたオリゴヌクレオチドであり、そして、各々は、フリーの3’−または5’−、好ましくは3’−ヒドロキシ基またはチオール基、特に好ましくは3’−ヒドロキシ基を、有している。
R13−X6−PX4X5
を有し、式中、R13は、リン保護基、一般的には、オリゴヌクレオチド合成に用いられる開裂可能なリン保護基、例えば、置換されたまたは未置換の脂肪族基またはアラルキル基であって、メチル基、−CH2CH2−Si(CH3)2C6H5、−CH2CH2−S(O)2−CH2CH3、−CH2CH2−C6H4−NO2のようなもの、好ましくは、式−CH2CH2CNの基;置換されたまたは未置換の芳香族基であって、フェニルまたは置換フェニルのようなもの、例えば、4−クロロフェニル基、2−クロロフェニル基、2−ニトロフェニル基または4−ニトロフェニル基であり;X6は、OまたはS、好ましくは、Oであり;X4およびX5は、同じであってよいしまたは異なっていてよくハロ(一般的にはブロモまたはクロロ)等の脱離基、または−NR14R15であり、ここにおいて、R14およびR15は、各々独立して、アルキル基、好ましくは、C1-6アルキル基であり、またはR14およびR15は接合し、それらが結合しているNと一緒に5〜7員環を形成する。一般的には、X4およびX5の少なくとも一つは、式−NR14R15の基である。最も好ましくは、X4およびX5は同じであり、X4およびX5双方が−N[CH(CH3)2]2基であるのが特に好適である。特に、X6がOであり、そしてR13が−CH2CH2CNであるのが好適である。
好ましいホスフィチル化剤の例には、O−β−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロジアミダイト(一般的には、「テトラホス(tetraphos)」として知られる)、O−β−シアノエチル−N,N,N’,N’−テトラメチルホスホロジアミダイト、O−β−シアノエチル−N,N,N’,N’−テトラエチルホスホロジアミダイト、ビス(N,N−ジイソプロピルアミノ)−2−メチルトリフルオロアセチルアミノエトキシホスフィン、ビス(N,N−ジイソプロピルアミノ)−2−ジフェニルメチルシリルエトキシホスフィンおよびO−β−シアノエチル−ビス(N−モルホリノ)ホスホロジアミダイトが含まれる。
好都合には、実質的に無水の反応条件を用いる。
本発明による方法は、好都合には、ヌクレオシドホスホロアミダイトを生成するために用いられる。したがって、本発明の好ましい側面は、式
を有する化合物と、式
NCCH2CH2O−P(N(R16)2)2
(式中、R16は、C1-6アルキル基、好ましくは、イソプロピル基である)
を有する化合物とを、活性化物質であって、式
多数の態様において、活性化物質は、アルコールに対して化学量論的モル比または化学量論より少ないモル比で用いられ、約0.4:1〜1:1、特に、約0.5:1〜0.75:1の活性化物質対アルコールのモル比が好適である。
脂肪族基、アリール基、アラルキル基、ヘテロアリール基、アザヘテロアリール基およびヘテロ脂環基に対する適した置換基には、アリール基、ハロゲン化アリール基、アルキル基、ハロゲン化アルキル(例えば、トリフルオロメチルおよびトリクロロメチル)、脂肪族エーテル類、芳香族エーテル類、ベンジル、置換ベンジル、ハロゲン類、特に、クロロ基およびフルオロ基、シアノ、ニトロ、−S−(脂肪族基または置換脂肪族基)および−S−(芳香族または置換芳香族)が含まれる。
本明細書中で用いられるヘテロアラルキル基は、アルキル基によってある部分に連結しているヘテロアリール置換基である。
実施例1
サッカリンのN−メチルイミダゾール塩を、次の手順によって製造した。サッカリンを、アセトニトリル中に懸濁させ、そしてその懸濁液に、サッカリンに対して1.1当量のN−メチルイミダゾールを滴下した。反応混合物を減圧下で濃縮して、結晶性塩を形成させ、それを、エーテルかまたはヘキサンで洗浄して、N−メチルイミダゾールおよびアセトニトリルの痕跡を除去した。
一連のヌクレオシドを、O−β−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロアミダイトと、活性化物質としてのサッカリンのN−メチルイミダゾール塩を用いてホスフィチル化した。
適当なサイズのフラスコ中に、ヌクレオシド(1.5mmol)を加え、その固体を、20mLのピリジンで2回蒸留すること(ロータリーエバポレーター)によって共沸乾燥させた。そのフラスコをArでパージし、そして15mLのアセトニトリルをフラスコに加えた。その混合物を、室温で、透明な溶液が得られるまで撹拌した。混合物に、O−β−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロアミダイト(Tetraphos)を加えた後、サッカリンのN−メチルイミダゾール塩を加えた。混合物を室温で撹拌し、同時に、反応の終点について、HPLCによって反応を監視した。反応の終了後、混合物を30mLの酢酸エチルで希釈し、そして有機混合物を、2x25mLの飽和重炭酸ナトリウム水溶液および25mLの飽和塩化ナトリウム水溶液で洗浄した。有機層を分離し、MgSO4上で乾燥させた。懸濁液を濾過し、そしてロータリーエバポレーターを用いて溶媒を除去した。残留物を真空下で乾燥させて、泡状物を生じた。
500mL丸底フラスコ中に、5’−DMT−N−Bz−2’−デオキシアデノシン(18.00g,27.37mmol)を加え、その固体を、2x200mLのトルエンの添加および蒸発(ロータリーエバポレーター)によって共沸乾燥させた。残留物を真空下で16時間乾燥させた。その残留物を、アルゴン雰囲気下においてアセトニトリル(180mL)中に溶解させ、そしてO−β−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロジアミダイト(9.90g,32.84mmol)を加えた。その混合物を5分間撹拌し、そしてサッカリンのN−メチルイミダゾール塩固体(3.63g,13.69mmol)を加えた。その混合物を室温で撹拌し、同時に、HPLCによって反応を監視した。18時間後、それ以上の反応は認められなくなった。反応混合物に、酢酸エチル(200mL)を加え、そして有機溶液を、飽和重炭酸ナトリウム水溶液(2x150mL)および飽和塩化ナトリウム水溶液(150mL)で洗浄した。有機層を分離し、MgSO4上で乾燥させた。懸濁液を濾過し、そしてロータリーエバポレーターを用いて溶媒を除去した。残留物を真空下で16時間乾燥させて、白色泡状物を生じた。
HPLC:92.5%
その粗生成物(23.70g)を、シリカゲル(230g)カラムを用いたクロマトグラフィーによって処理した。カラムは、0.5%トリエチルアミンを含有する30%酢酸エチル/ヘキサンを用いて充填された。そのカラムを、2カラム容量の30%酢酸エチル/ヘキサンで洗浄した。粗生成物を充填し、そしてそのカラムを、2カラム容量の30%酢酸エチル/ヘキサン、2カラム容量の40%酢酸エチル/ヘキサン、2カラム容量の50%酢酸エチル/ヘキサン、そして最後に、3カラム容量の70%酢酸エチル/ヘキサンを用いて溶離した。TLC(8:3の酢酸エチル:ヘキサン)によって生成物が検出された場合、画分を集めた。所望の生成物を含有する画分を一緒に、ロータリーエバポレーターを用いて溶媒を除去した。残留物を真空下で16時間乾燥させて、白色泡状物を生じた。
HPLC:97.5%
31P NMR:99.3%
Claims (13)
- X7がOであり、pが0である、請求項1に記載の方法。
- 式1の化合物を、有機塩基との塩錯体として用いる、請求項1または請求項2に記載の方法。
- 有機塩基が、ピリジン、3−メチルピリジンおよびN−メチルイミダゾールから成る群より選択される、請求項3に記載の方法。
- アルコールまたはチオールが、フリーのヒドロキシ基またはチオール基を含むヌクレオシドまたはオリゴヌクレオチドである、請求項1〜4のいずれかに記載の方法。
- フリーの3’−ヒドロキシ基を含むヌクレオシドをホスフィチル化する、請求項5に記載の方法。
- ホスフィチル化剤が、一般化学式
R13−X6−PX4X5
(式中、R13はリン保護基であり、X6は、OまたはSであり、X4およびX5は、同じであってよいしまたは異なっていてよく、脱離基である)
を有する、請求項1〜6のいずれかに記載の方法。 - R13が、置換されたまたは未置換の脂肪族基またはアラルキル基、または置換されたまたは未置換の芳香族基であり、X6がOであり、そしてX4およびX5が、各々独立して、−NR14R15であり、ここにおいて、R14およびR15は、各々独立して、C1-6アルキル基であり、またはR14およびR15は接合し、それらが結合しているNと一緒に5〜7員環を形成する、請求項7に記載の方法。
- ホスフィチル化剤が、O−β−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロジアミダイト、O−β−シアノエチル−N,N,N’,N’−テトラメチルホスホロジアミダイト、O−β−シアノエチル−N,N,N’,N’−テトラエチルホスホロジアミダイト、ビス(N,N−ジイソプロピルアミノ)−2−メチルトリフルオロアセチルアミノエトキシホスフィン、ビス(N,N−ジイソプロピルアミノ)−2−ジフェニルメチルシリルエトキシホスフィンおよびO−β−シアノエチル−ビス(N−モルホリノ)ホスホロジアミダイトから成る群より選択される、請求項8に記載の方法。
- 式
NCCH2CH2O−P(N(R16)2)2
を有する化合物とを、活性化物質であって、式
- 有機塩基が、ピリジン、3−メチルピリジンおよびN−メチルイミダゾールから成る群より選択される、請求項10に記載の方法。
- R5が、H、OMeまたはOCH2CH2OMeである、請求項10または請求項11に記載の方法。
- R4が、酸に不安定な保護基であり、そしてR5がOR6であり、ここにおいて、R6が、塩基に不安定な保護基またはシリル保護基である、請求項10または請求項11に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41818502P | 2002-10-15 | 2002-10-15 | |
US60/418,185 | 2002-10-15 | ||
PCT/GB2003/004312 WO2004035599A1 (en) | 2002-10-15 | 2003-10-08 | Phosphitylation process |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006508081A true JP2006508081A (ja) | 2006-03-09 |
JP4756863B2 JP4756863B2 (ja) | 2011-08-24 |
Family
ID=32107901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004544427A Expired - Lifetime JP4756863B2 (ja) | 2002-10-15 | 2003-10-08 | ホスフィチル化方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7247720B2 (ja) |
EP (1) | EP1554300B1 (ja) |
JP (1) | JP4756863B2 (ja) |
KR (1) | KR101065715B1 (ja) |
CN (1) | CN1329408C (ja) |
AT (1) | ATE362937T1 (ja) |
AU (1) | AU2003269239A1 (ja) |
CA (1) | CA2501565C (ja) |
DE (1) | DE60313993T2 (ja) |
WO (1) | WO2004035599A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021141072A1 (ja) * | 2020-01-08 | 2021-07-15 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
WO2023140040A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人東海国立大学機構 | アミダイトモノマー |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR036122A1 (es) * | 2001-07-03 | 2004-08-11 | Avecia Biotechnology Inc | Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita |
GB0229443D0 (en) * | 2002-12-18 | 2003-01-22 | Avecia Ltd | Process |
KR102834624B1 (ko) * | 2019-10-18 | 2025-07-15 | 후지필름 와코 준야쿠 가부시키가이샤 | 포스포아미다이트 활성화제 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062922A1 (en) * | 1998-06-02 | 1999-12-09 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
JP2004533488A (ja) * | 2001-07-03 | 2004-11-04 | アベシア・バイオテクノロジー・インコーポレーテッド | オリゴヌクレオチド合成用のアクチベーター |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034534A (en) * | 1988-07-15 | 1991-07-23 | E. I. Du Pont De Nemours And Company | Process for producing saccharin, saccharin analogues or their salts |
US5662111A (en) * | 1991-01-28 | 1997-09-02 | Cosman; Eric R. | Process of stereotactic optical navigation |
US6034534A (en) * | 1995-05-25 | 2000-03-07 | Kiyota; Shigeo | Laminated contact probe for inspection of ultra-microscopic pitch |
-
2003
- 2003-10-08 US US10/531,323 patent/US7247720B2/en not_active Expired - Lifetime
- 2003-10-08 DE DE60313993T patent/DE60313993T2/de not_active Expired - Lifetime
- 2003-10-08 CN CNB2003801014035A patent/CN1329408C/zh not_active Expired - Lifetime
- 2003-10-08 KR KR1020057006226A patent/KR101065715B1/ko not_active Expired - Lifetime
- 2003-10-08 EP EP03751018A patent/EP1554300B1/en not_active Expired - Lifetime
- 2003-10-08 JP JP2004544427A patent/JP4756863B2/ja not_active Expired - Lifetime
- 2003-10-08 CA CA2501565A patent/CA2501565C/en not_active Expired - Lifetime
- 2003-10-08 WO PCT/GB2003/004312 patent/WO2004035599A1/en active IP Right Grant
- 2003-10-08 AU AU2003269239A patent/AU2003269239A1/en not_active Abandoned
- 2003-10-08 AT AT03751018T patent/ATE362937T1/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062922A1 (en) * | 1998-06-02 | 1999-12-09 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
JP2004533488A (ja) * | 2001-07-03 | 2004-11-04 | アベシア・バイオテクノロジー・インコーポレーテッド | オリゴヌクレオチド合成用のアクチベーター |
Non-Patent Citations (1)
Title |
---|
JPN5003021591, MORIGUCHI, J. ORG. CHEM., 2000, V65, P8229−8238 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021141072A1 (ja) * | 2020-01-08 | 2021-07-15 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
JPWO2021141072A1 (ja) * | 2020-01-08 | 2021-07-15 | ||
JP7657736B2 (ja) | 2020-01-08 | 2025-04-07 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
WO2023140040A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人東海国立大学機構 | アミダイトモノマー |
Also Published As
Publication number | Publication date |
---|---|
US7247720B2 (en) | 2007-07-24 |
DE60313993D1 (de) | 2007-07-05 |
CA2501565C (en) | 2011-03-15 |
KR101065715B1 (ko) | 2011-09-19 |
EP1554300B1 (en) | 2007-05-23 |
JP4756863B2 (ja) | 2011-08-24 |
AU2003269239A1 (en) | 2004-05-04 |
DE60313993T2 (de) | 2008-01-24 |
ATE362937T1 (de) | 2007-06-15 |
US20060069247A1 (en) | 2006-03-30 |
EP1554300A1 (en) | 2005-07-20 |
CN1705675A (zh) | 2005-12-07 |
CN1329408C (zh) | 2007-08-01 |
KR20050055004A (ko) | 2005-06-10 |
CA2501565A1 (en) | 2004-04-29 |
WO2004035599A1 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8093397B2 (en) | Activators for oligonucleotide synthesis | |
EP1409497B1 (en) | Method for preparation of lna phosphoramidites | |
US7153954B2 (en) | Method for preparation of LNA phosphoramidites | |
US6846922B1 (en) | Activators for oligonucleotide synthesis | |
JPH01301691A (ja) | 新規ヌクレオチド誘導体 | |
CA2192950A1 (en) | Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | |
JP4756863B2 (ja) | ホスフィチル化方法 | |
DE60109047T2 (de) | Synthone zur herstellung von oligonukleotiden | |
KR100228606B1 (ko) | 올리고뉴클레오티드의 화학적 합성 방법 | |
EP1899361B1 (en) | Reagent for the improved synthesis of isoguanosine-containing oligonucleotides | |
BR112020005067B1 (pt) | Fosforamiditas nucleosídeo modificadas, composição, e métodos para produzir um oligonucleotídeo | |
BR112020005067A2 (pt) | fosforamiditas nucleosídeo modificadas | |
BR122024007782A2 (pt) | Fosforamiditas nucleosídeo modificadas, composição compreendendo as mesmas e métodos para produzir um oligonucleotídeo | |
WO2003045969A1 (en) | Coupling reagent for h-phosphonate chemistry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100602 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101029 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110513 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110531 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4756863 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140610 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140610 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140610 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |